D-1388-2019 Class II Terminated

Recalled by Sun Pharmaceutical Industries, Inc. — Cranbury, NJ

FDA drug recall D-1388-2019 was initiated by Sun Pharmaceutical Industries, Inc. on Jun 5, 2019 and is designated Class II. Reason for recall: Testing of Fexofenadine HCl and Pseudoephedrine Failed Impurities/Degradation Specifications: elevated substance results that were reported above or near the specification limit The recall status is terminated (terminated Jan 8, 2021). Affected quantity: 17,136 20-count units.

Recall details

Product Type
Drugs
Report Date
Jun 26, 2019
Initiation Date
Jun 5, 2019
Termination Date
Jan 8, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
17,136 20-count units

Product description

Allergy Relief D, Fexofenadine HCl 60 mg/ Pseudoephedrine HCl 120 mg, Extended Release Tablets, USP, 20-count box, Distributed by: CVS Pharmacy, Inc. One CVS Drive, Woonsocket, RI 02895. Made in India. UPC 0 50428 43023 1

Reason for recall

Testing of Fexofenadine HCl and Pseudoephedrine Failed Impurities/Degradation Specifications: elevated substance results that were reported above or near the specification limit

Distribution pattern

Nationwide in the USA

Code information

Lot GKT0791, EXP 06/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1388-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1388-2019. Report a data issue: hello@regdatalab.com.